Biotech

Sanofi

Biotech

Sanofi halts phase 3 autoimmune trial early over lackluster data

The setback eliminates one opportunity for a key late-phase program and continues the “bumpy ride” for Sanofi’s pipeline.

Nick Paul Taylor Jun 10, 2026 4:25am

Magnifying glass focusing on number 2026 with target icon on yellow background

Despite headwinds, biotech industry charges forward behind M&A

Jun 9, 2026 12:41pm

How AI is reshaping biopharma decision-making

How AI is reshaping biopharma decision-making

Brought to you by Clarivate

rollercoaster ride theme park scary crazy

Parabilis ups planned IPO haul to record-setting $637M

Jun 9, 2026 10:22am

Managing complexity across biopharma modalities

Managing complexity across biopharma modalities

Brought to you by SK Pharmteco

AlzeCure

Lilly licenses AlzeCure Alzheimer’s asset for $1B biobucks

Jun 9, 2026 10:16am